

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/159949 A1

(51) International Patent Classification:
C07K 14/605 (2006.01)

(21) International Application Number:
PCT/US2020/015353

(22) International Filing Date:
28 January 2020 (28.01.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/797,963 29 January 2019 (29.01.2019) US
62/815,053 07 March 2019 (07.03.2019) US
62/818,342 14 March 2019 (14.03.2019) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **COFFIN, Stephanie Ruth**; c/o Eli Lilly
And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **FREDERICK, Michael Oliver**; c/o Eli
Lilly And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **JALAN, Ankur**; C/o Eli Lilly And Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **KALLMAN, Neil John**; C/o Eli Lilly And Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **KOPACH, Michael Eugene**; c/o Eli Lilly And Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **SEIBERT, Kevin Dale**; c/o Eli Lilly And Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **TSUKANOV, Sergey Vladimirovich**; c/o Eli Lil-
ly And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US).

(74) Agent: **VORNDRAN-JONES, MaCharri, R.** et al.; Eli
Lilly And Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

WO 2020/159949 A1

(54) Title: PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST

(57) Abstract: The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.